Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants - Importance of design.
作者信息
Zhaori Getu
机构信息
Editorial Office, Pediatric Investigation, Beijing Children's Hospital Capital Medical University, National Center for Children's Health Beijing China.
出版信息
Pediatr Investig. 2023 May 10;7(2):144-146. doi: 10.1002/ped4.12377. eCollection 2023 Jun.
Abstract
摘要
相似文献
1
Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants - Importance of design.
Pediatr Investig. 2023 May 10;7(2):144-146. doi: 10.1002/ped4.12377. eCollection 2023 Jun.
2
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
MMWR Morb Mortal Wkly Rep. 2024 Mar 7;73(9):209-214. doi: 10.15585/mmwr.mm7309a4.
3
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
Expert Opin Investig Drugs. 2022 Jan;31(1):23-29. doi: 10.1080/13543784.2022.2020248. Epub 2021 Dec 28.
4
Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).
An Pediatr (Engl Ed). 2023 Oct;99(4):257-263. doi: 10.1016/j.anpede.2023.09.006. Epub 2023 Sep 22.
5
The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study.
Front Public Health. 2024 Aug 16;12:1441786. doi: 10.3389/fpubh.2024.1441786. eCollection 2024.
6
Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.
Vaccine. 2024 Aug 30;42(21):126164. doi: 10.1016/j.vaccine.2024.126164. Epub 2024 Jul 30.
7
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556.
8
Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
Nurs Womens Health. 2024 Feb;28(1):75-79. doi: 10.1016/j.nwh.2023.11.002. Epub 2023 Dec 6.
9
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
N Engl J Med. 2023 Dec 28;389(26):2425-2435. doi: 10.1056/NEJMoa2309189.
10
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9.
引用本文的文献
1
Layer-by-Layer Microparticle Vaccines Containing a S177Q Point Mutation in the Central Conserved Domain of the RSV G Protein Improves Immunogenicity.
Viral Immunol. 2025 Apr;38(3):107-119. doi: 10.1089/vim.2024.0084. Epub 2025 Mar 24.
本文引用的文献
1
Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.
N Engl J Med. 2023 Feb 16;388(7):609-620. doi: 10.1056/NEJMoa2207566.
2
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604.
3
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9.
4
Nirsevimab: First Approval.
Drugs. 2023 Feb;83(2):181-187. doi: 10.1007/s40265-022-01829-6.
5
Antibodies to watch in 2023.
MAbs. 2023 Jan-Dec;15(1):2153410. doi: 10.1080/19420862.2022.2153410.
6
A Challenge to Respiratory Syncytial Virus Illness in Adults.
N Engl J Med. 2022 Jun 23;386(25):2427-2428. doi: 10.1056/NEJMe2205701.
7
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
N Engl J Med. 2022 Jun 23;386(25):2377-2386. doi: 10.1056/NEJMoa2116154.
8
Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.
N Engl J Med. 2022 Apr 28;386(17):1615-1626. doi: 10.1056/NEJMoa2106062.
9
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
N Engl J Med. 2022 Mar 3;386(9):892-894. doi: 10.1056/NEJMc2112186.
10
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275.
Zotero 插件